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Abstract: Brain neurons and tissues respond to sublethal injury by activating endogenous 
protective pathways. Recently, following the failure of a large number of clinical trials for 
protective strategies against stroke that aim to inhibit a specific ischemia response pathway, 
endogenous neuroprotection has emerged as a more promising and hopeful strategy for 
development of therapeutics against stroke and neurodegenerative disorders. Neuroglobin 
(Ngb) is an oxygen-binding globin protein that is highly and specifically expressed in brain 
neurons. Accumulating evidence have clearly demonstrated that Ngb is an endogenous 
neuroprotective molecule against hypoxic/ischemic and oxidative stress-related insults in 
cultured neurons and animals, as well as neurodegenerative disorders such as Alzheimer’s 
disease, thus any pharmacological strategy that can up-regulate endogenous Ngb 
expression may lead to novel therapeutics against these brain disorders. In this review, we 
summarize recent studies about the biological function, regulation of gene expression, and 
neuroprotective mechanisms of Ngb. Furthermore, strategies for identification of chemical 
compounds that can up-regulate endogenous Ngb expression for neuroprotection against 
stroke and neurodegenerative disorders are discussed. 
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1. Introduction 
In the past 20 years, a large number of clinical trials for neuroprotectants against stroke and 
neurodegenerative disorders have yielded mostly disappointing outcomes. Nevertheless, enormous 
knowledge has been learnt from these trials and related basic investigations. In particular, 
preconditioning studies have demonstrated that activation of endogenous protective mechanisms can 
prevent or limit brain damage. Activation of these endogenous protective mechanisms could be a more 
promising strategy for the development of new therapies against stroke and neurodegenerative 
disorders. Neuroglobin (Ngb) is an oxygen-binding globin protein that is highly and specifically 
expressed in brain neurons[1]. Accumulating evidence has proved that Ngb is an endogenous 
neuroprotective molecule against hypoxic/ischemic insults in cultured neurons and animals. Enhanced 
Ngb gene expression inversely correlates with the severity of histological and functional deficits after 
ischemic stroke [2–5], while Ngb knock-down deteriorates the outcome of hypoxic/ischemic brain 
injury [6]. Furthermore, Ngb overexpression is also protective against beta-amyloid-induced 
neurotoxicity and transgenic Alzheimer phenotype in vivo [7]. These findings strongly suggest that 
pharmacological strategies that can up-regulate endogenous Ngb expression may be developed into a 
novel therapeutic approach for stroke intervention. Here we review the recent experimental findings 
from our laboratory and others about Ngb’s biological function, regulation of gene expression,  
and neuroprotection mechanisms. Additionally, we discuss strategies to identify chemical compounds 
that can up-regulate endogenous Ngb expression for neuroprotection against stroke and   
neurodegenerative disorders. 
2. Ngb Can Serve as a Target for Development of Therapeutics against Stroke and 
Neurodegenerative Disorders   
Endogenous protection pathways can be activated in the brain in response to a wide variety of 
stimuli, in which a large number of proteins are involved and show protective effects [8]. Endogenous 
neuroprotective molecules, including transcription factors, have been considered new therapeutic 
targets against stroke or related disorders [9]. Since elevated levels of these molecules are related to 
improved physiological outcomes, strategies that can up-regulate the expression of these molecules are 
expected to be neuroprotective.   
One of the endogenous neuroprotective molecules is Ngb, whose broad neuroprotective effects 
against stroke and neurodegenerative disorders have been demonstrated by a series of experimental 
studies [10–14]. Since Ngb is an intracellular protein that normally does not cross cell membranes, 
except in zebrafish [15], delivery of exogenous Ngb protein is generally considered unfeasible as a 
therapy, especially for CNS disorders such as stroke, thus seeking small molecules capable of 
up-regulating endogenous Ngb may lead to the development of new approaches for the treatment of 
stroke and related disorders. Indeed, a couple of groups have recently reported that Ngb can be Int. J. Mol. Sci. 2012, 13 6997 
 
up-regulated by a few chemical compounds, including valproic acid, cinnamic acid and   
17β-estradiol [16,17], which is a good start to develop Ngb-targeted therapeutics against stroke and 
neurodegenerative disorders. In addition, the discovery of these preliminary Ngb stimulators may  
serve as positive controls in the future establishment of a larger scale screening system for  
Ngb-stimulating compounds.   
3. Neuroprotective Roles of Ngb against Hypoxic/Ischemic and Oxidative Stress-Related 
Brain/Neuron Injury   
Globins, including hemoglobin, myoglobin and cytoglobin, are oxygen-binding proteins that widely 
exist and play important roles in many taxa, including bacteria, plant, fungi and animals. In 2000, Ngb 
was for the first time identified as a new globin family member that is highly expressed in brain 
neurons [1]. Ngb is evolutionally highly conserved, with mouse and human Ngb sharing 94% identity 
in protein sequence. Besides brain neurons, Ngb is also highly expressed in the peripheral nervous 
system, endocrine tissues and retina [18]. Since the discovery of Ngb, a large array of experimental 
studies have approved its neuroprotective functions and looked into possible underlying mechanisms, 
which have been extensively summarized in several review articles [13,19–24].   
The oxygen-binding property and neuron specific expression of Ngb are strong indications of Ngb’s 
neuroprotection role against hypoxic/ischemic neuron injury. Gene expression alteration approaches 
have been applied to address this issue. The first report in this category by Sun et al. showed that 
antisense-mediated knock-down of Ngb rendered cortical neurons more vulnerable to hypoxia, 
whereas Ngb overexpression conferred protection of cultured neurons against hypoxia [2]. A similar 
effect was observed in the neuroblastoma cell line SH-SY5Y, that Ngb over-expression enhanced cell 
survival under conditions of anoxia or oxygen and glucose deprivation (OGD) [25]. In animal stroke 
models, Ngb-overexpression by adeno-associated virus administration significantly reduced infarct 
size in rats following middle cerebral artery occlusion (MCAO), and the outcome was reversed when 
Ngb was knocked down using anti-sense oligonucleotide [6]. In the Ngb-overexpressing transgenic 
(Ngb-Tg) mice, Dr. Greenberg’s group found that the cerebral infarct size after MCAO was reduced by 
approximately 30% compared to wild type [26]. Our lab also tested the neuroprotective effects of Ngb 
in transient focal cerebral ischemia using our own Ngb-overexpressing transgenic mouse line [5]. Our 
results were broadly consistent with the study by Dr. Greenberg’s group [26], and further documented 
that the reduction of brain infarction in Ngb-overexpressing transgenic mice can be sustained up to  
14 days after ischemia compared to wild type controls, suggesting that Ngb overexpression is 
neuroprotective against transient focal cerebral ischemia, but the involved mechanisms need to be 
further characterized. It should be noted that the above experiments with Ngb transgenic approaches 
are “outcome” studies. These findings are very informative about the effects of artificially increased 
Ngb level on stroke, but have limitations to fundamentally define or interpret the role of endogenous 
Ngb, thus in the future, a neuron-specific and inducible Ngb knockdown approach would be very 
useful in further investigations of Ngb function in the normal, versus ischemic, brain.   
Previous studies on the neuroprotective effects of Ngb are mostly based on models using transgenic 
overexpression approaches. However, for stroke therapy, it would be more practical and easily 
applicable if increased Ngb protein level in brain tissue can be achieved after stroke. A recent report by Int. J. Mol. Sci. 2012, 13 6998 
 
Cai et al. [27] presented important progress toward this direction. They delivered Ngb protein into 
mouse brain tissue using the 11-amino-acid human immunodeficiency virus trans-activator of the 
transcription (TAT) protein transduction domain. The results showed that the brain tissue was protected 
from ischemic stroke by both pre-treatment of TAT-Ngb or post-treatment right after reperfusion onset 
in a mild MCAO mouse model, but no beneficial outcome was observed if the TAT-Ngb was 
administered 2 hr after ischemia onset. This study suggests that Ngb-overexpression might be beneficial 
for early stroke treatment, and for stroke prevention for individuals with higher stroke risk as well.   
4. Neuroprotective Effects of Ngb against Neurodegenerative and Other Neurological Disorders   
As a brain specific oxygen-binding protein, it is not surprising that Ngb is also protective against 
other models of neurological disorders. One example is that Ngb overexpression was protective against 
beta-amyloid and NMDA toxicity in both cultured neurons and in the Alzheimer’s disease (AD) model 
of mice [7,28]. Additionally, Ngb expression can be up-regulated in the cerebellum of rat pups exposed 
to maternal epileptic seizures, implying that Ngb may also be protective against seizures [29]. Our 
recent study showed that Ngb overexpression protects retinal ganglion cells (RGC) against ocular 
hypertension and glaucomatous damage [30]. The broader implication of Ngb in neurodegenerative 
disorders indicates the importance of Ngb as an endogenous neuroprotective molecule, therefore any 
strategy that can up-regulate endogenous Ngb expression is more likely to be clinically beneficial.   
5. Molecular Mechanisms of Ngb Neuroprotection   
It has been widely accepted that Ngb is protective against hypoxic/ischemic brain injury [5,26], 
however, the underlying mechanisms remain poorly defined. Initial evidence suggests that the 
neuroprotective effect of Ngb may be largely linked to its structural features in O2 and NO binding. 
Furthermore, putative signal transduction and mitochondrial function preservation may also be 
involved in the protective mechanisms.   
5.1. Oxygen Sensing and ROS Scavenging by Ngb 
Ngb protein in human or mouse exists as a monomer, which is distinct from the heterotetrameric 
hemoglobins. The 3D structure of human [31] or mouse Ngb [32] has been solved, showing that the 
heme is inserted into the protein in two different orientations. The lack of orientation selectivity is 
possibly related to the presence of a large cavity lining the heme and to the increased mobility of heme 
contacts [32]. Human Ngb displays a typical globin fold, and the heme-iron is hexacoordinate [33], 
with proximal HisF8 and distal HisE7 that provide the two axial coordination bonds. An elongated 
protein matrix cavity in the 3D structure would facilitate O2 diffusion to the heme [34]. Ngb was 
originally thought to function in O2 storage and transportation, however, since Ngb has a very high O2 
binding rate and low O2 dissociation rate, and Ngb protein concentration in the brain is relatively low 
(~1 μM) [20], thus O2 storage and transportation might not be Ngb’s main function, instead, Ngb may 
function in O2 sensing [35,36].   
A number of studies have indicated that Ngb’s neuroprotection role is related to its ability in 
scavenging reactive species, because Ngb can directly bind to nitric oxide (NO) with high intrinsic 
affinity and a low dissociation rate [37]. In support of this function, a high degree of co-localization of Int. J. Mol. Sci. 2012, 13 6999 
 
neuronal nitric oxide synthase (nNOS) and Ngb has been detected within anterior basomedial 
amygdala (BMA), lateral hypothalamus and laterodorsal tegmental nucleus (LDTg) [38], implying that 
in these neurons, NO could be the endogenous ligand for Ngb. Furthermore, Brunori et al. [39] found 
that the oxygenated derivative of Ngb, Ngb-O2, reacts with NO rapidly to produce NO3
− and met-Ngb. 
This pathway would dispose of NO and may in turn protect cellular respiration jeopardized by the 
inhibitory effect of NO on cytochrome c oxidase activity [40,41]. Additionally, Ngb overexpression 
rendered HN33 neuroblastoma cells more resistant to NO-induced cell death compared to wild type 
cells, suggesting the ability of Ngb in neutralizing the neurotoxic effects of reactive nitrogen  
species [42]. Ngb was also shown to be protective against other oxidative challenges in cultured 
neurons. For example, Ngb-overexpression conferred protection in SH-SY5Y cells directly injured by 
H2O2 [43]. Furthermore, beta-amyloid-induced cytotoxicity to PC12 cells, marked by reactive oxygen 
species production and lipids peroxidation, was ameliorated by Ngb overexpression [44]. All of these 
findings suggest that Ngb may have the function of reactive oxygen species scavenging.   
5.2. Regulation of Signal Transduction   
In addition to the possible O2 sensing and ROS scavenging functions described above, Ngb has also 
been hypothesized to act as a signal transducer. Dr. Morishima’s lab found that ferric human Ngb 
(met-Ngb) binds to the GDP-bound state of G protein α subunit (Gα), and exerts guanine-nucleotide 
dissociation inhibitor (GDI) activity [45]. Ferric Ngb inhibits the exchange of GDP for GTP, thus 
prevents the Gα subunit from binding to the Gβγ complex and activates the downstream signal 
transduction pathway, which is protective against oxidative stress [46]. This hypothesis was 
additionally supported by the observation that the guanine-nucleotide dissociation inhibitor activity of 
human Ngb is required for its neuroprotection for PC12 cells under oxidative stress [47].   
Khan et al. have shown that Ngb binds two members of the Rho GTPase family, Rac1 and Rho A, 
as well as the Pak1 kinase, a key regulator of actin assembly and Rho-GDI-GTPase signaling complex 
activity under hypoxia [48]. They hypothesized that Ngb may play a neuroprotective role by inhibiting 
the dissociation of the GTPase Rac-1 from its endogenous GDI, which can reduce hypoxia-induced 
actin polymerization and microdomain aggregation. Moreover, Ngb was also found to interact with 
other targets, such as flotillin-1 (a lipid raft microdomain-associated protein) [49] and cystatin C  
(a cysteine protease inhibitor) [50], the latter proposing a possibility that Ngb modulates the 
intracellular transport of cystatin C to protect against neuronal death caused by oxidative stress. 
Based on the above findings and the kinetics study of Ngb reaction with O2 and NO, Brunori et al. 
proposed that Ngb might function as a sensor of the relative O2 and NO concentrations in the  
tissue [39]. Supportive evidence for this hypothesis is that Ngb oxygenation is quickly reversible, and 
the oxygenated derivative, Ngb-O2, reacts rapidly with NO to produce NO3
− and met-Ngb. This 
process competes effectively with the direct formation of Ngb-NO, which excludes the production of 
met-Ngb, and its protective signaling function as a guanine-nucleotide dissociation inhibitor [45].  
On the other hand, Tsio et al. [51] reported that human Ngb can function as a redox-regulated nitrite 
reductase as deoxygenated human Ngb can convert nitrate to NO. These studies suggest that Ngb may 
function as a physiological oxidative stress sensor and may regulate intracellular hypoxic 
NO-signaling pathways. Int. J. Mol. Sci. 2012, 13 7000 
 
The proper function of Ngb requires a met-Ngb reductase to maintain the balance between redox 
and oxidized Ngb. Complying with this scenario, Dr. Brunori’s lab found that NADH:flavorubredoxin 
oxidoreductase (FlRd-red) from E. coli is able to slowly reduce Ngb at catalytic concentrations [52]. 
More interestingly, E. coli FlRd-red was found to share significant similarity with human 
apoptosis-inducing factor (AIF), the principal mediator of the so-called caspase-independent 
programmed cell death [53]. In healthy cells, AIF is located within the mitochondrion, but upon 
permeabilization of mitochondrial outer membrane, it translocates first to the cytosol and then to the 
nucleus, where it triggers chromatin condensation followed by massive DNA fragmentation [53]. It is 
therefore possible that AIF may reduce cytoplasmic met-Ngb on its way from the mitochondrion to 
nucleus, and depending on O2 tension, the reduced Ngb can either interfere with the classical apoptotic 
pathway by reducing ferric Cytochrome c (Cyt c) [54] or become involved in NO scavenging [39].  
Previous studies have suggested that Ngb is very likely to function in multiple pathways leading to   
its neuroprotection role, as described above. Based on this, our laboratory has hypothesized that Ngb 
may also play a role in regulating gene expression in response to hypoxia/OGD; we therefore 
performed a microarray screening to examine the effect of Ngb overexpression on the expression of 
hypoxic-response genes in mouse cortical neurons. We found that 20 genes were downregulated at 
early phase OGD/Reoxygenaton in wild type neurons, while 12 of them were no longer significantly 
changed in Ngb-overexpressing neurons [55]. These genes are broadly involved in neuronal function 
and survival, indicating that Ngb may play roles in multiple cell survival signaling pathways.   
Another example of Ngb involvement in signal transduction was found in the animal model of 
Alzheimer’s Disease (AD). Ngb has been shown to attenuate beta-amyloid-induced neurotoxicity [7]. 
As a potential molecular mechanism involved in this effect, it was found that Ngb overexpression 
attenuates tau hyperphosphorylation, a characterized pathological hallmark of AD brains, probably 
through activating the Akt signaling pathway [56]. One should note that almost all of these tests are 
“correlation” studies; the role of Ngb in these signaling pathways might be direct or indirect. Direct 
and causative evidence is still largely lacking. Nonetheless, Ngb has been demonstrated to be 
protective in stroke, AD, and could serve as a therapeutic target. 
5.3. Maintenance of Mitochondrial Function   
Ngb expression has been shown to be confined to metabolically active, oxygen-consuming cell 
types [21]. At the subcellular level, Ngb is associated with mitochondria and thus linked to the 
oxidative metabolism [57]. Mitochondria play key roles in energy production, ROS homeostasis, and 
cell death signaling. Mitochondria respond to various insults to cells, and its dysfunction is associated 
with a large variety of clinical phenotypes. It has been demonstrated that mitochondria comprises  
a central locus for energetic perturbations and oxidative stress in hypoxia/ischemia [58,59]. 
Experimental studies have shown that overexpression of Ngb promotes cell survival of PC12 cells 
against beta-amyloid toxicity and attenuates beta-amyloid-induced mitochondrial dysfunction [60]; 
and eliminates hypoxia-induced mitochondrial aggregation and neuron death [48]. Our lab also 
demonstrated that Ngb overexpression improves mitochondrial function and reduces oxidative stress 
after hypoxic insult in cultured mouse cortical neurons [61]. We found that at earlier time points after 
hypoxia/reoxygenation, no difference in neurotoxicity was observed between Ngb-overexpressing and Int. J. Mol. Sci. 2012, 13 7001 
 
wild type neurons, whereas the rates of decline of several mitochondria function biomarkers, including 
ATP level, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
 bromide (MTT) reduction, and 
mitochondrial membrane potential, were significantly ameliorated in Ngb-overexpressing neurons 
compared to wild type. At a later time point there was a significant reduction of neurotoxicity in 
Ngb-overexpressing neurons. Furthermore, Ngb overexpression reduced superoxide anion generation 
after hypoxia/reoxygenation, but glutathione levels were significantly improved, compared to wild  
type controls. Our data suggested that Ngb might affect both mitochondrial function and free radical 
generation as its potential neuroprotective mechanisms. However, there are multiple and probably 
inextricable feedback loops between preservation of mitochondrial energetics versus direct free radical 
scavenging [59,62–64]. We acknowledge that it will likely be impossible to unequivocally separate 
mitochondrial effects versus reactive oxygen species effects of Ngb. 
Hypoxia and OGD result in mitochondrial depolarization [65]. The mitochondrial permeability 
transition pore (mPTP) is a protein pore formed across the inner and outer membrane of the 
mitochondria under pathological conditions such as stroke. In response to hypoxia/ischemia, mPTP 
opening caused release of Cyt c from mitochondria to cytosol [66], followed by activation of 
caspase-dependent or -independent apoptosis pathways [67–69]. Studies in our lab have shown that 
Ngb overexpression is correlated with reduced mPTP opening, and decreased Cyt c release as well 
(unpublished data). This suggests an inhibitory role of Ngb in OGD-induced mPTP opening, which has 
been thought to be one of the major causes of cell death in a variety of tissue ischemic damage 
scenarios, as occurs in heart attack and stroke. Thus Ngb inhibitory effect in mPTP opening may be an 
important mechanism of Ngb neuroprotection.   
To further dissect the molecular mechanisms of Ngb neuroprotection, our laboratory recently did a 
screening for the protein interaction partners of mouse Ngb, using yeast two-hybrid assay. We 
identified several Ngb-binding proteins, including Na/K ATPase beta 1, cytochrome c1, ubiquitin C, 
voltage-dependant anion channel (VDAC) and a few more [70]. Among these Ngb-binding protein 
candidates, some are biologically important for neuronal function and survival. For example, 
cytochrome c1 is a subunit of the cytochrome bc1 complex (mitochondria complex III), which plays an 
important role in mitochondria function for energy transduction and generation of the superoxide  
anion [71], and it also plays pathological roles in response to oxidative stress [72,73] and regulates 
hypoxia-inducible-factor-1 activation induced by hypoxia [74–76]. Cytochrome c1 is localized in the 
intermembrane space between the outer and inner membrane of mitochondria [77]. The mitochondrial 
outer membrane contains the protein “porin”, which forms an aqueous channel through which proteins 
up to 10 kd can pass and go into the intermembrane space. It has been known that hypoxia-induced 
superoxide, as well as apoptotic signaling molecules, such as Bax, may cause permeabilization of the 
mitochondrial outer membrane [78,79]. Thus, as a 16 kd monomer, Ngb might be able to pass the outer 
membrane to bind and affect the function of cytochrome c1. Additionally, results from our laboratory 
showed that Ngb overexpression is able to decrease OGD-induced mitochondria permeability 
transition pore (mPTP) opening and Cyt c release from mitochondria. The interaction between Ngb 
and VDAC, an mPTP component, is supportive of Ngb’s effect in mPTP. However, the phenomenon of 
Ngb binding to other proteins and binding status-correlated alteration of cell signaling and 
mitochondrial function requires further investigation. The major hypotheses about Ngb-involved 
signaling pathways are summarized in Figure 1. Int. J. Mol. Sci. 2012, 13 7002 
 
Figure 1. Possible molecular mechanisms of  Ngb neuroprotection by modulating cell 
death/survival signaling pathways. Ngb may function as an O2 and NO sensor. Ngb has 
guanine-nucleotide dissociation inhibitor (GDI) activity and can prevent Gα from binding 
to the Gβγ complex and activates the downstream signaling pathway. Ngb may inhibit the 
dissociation of Rac-1 from its endogenous GDI, thus preventing hypoxia-induced actin 
polymerization and microdomain aggregation. Ngb may interact with VDAC and inhibit 
hypoxia/OGD-induced mPTP opening and Cyt c release from mitochondria. Ngb could 
convert Cyt c
3+ to Cyt c
2+, and subsequently interfere with apoptotic signaling cascades or 
scavenge nitric oxide. Ngb may interact with Cyc1 and inhibit hypoxia/OGD-induced ROS 
generation by mitochondria complex III. 
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6. Tissue Specific Expression of Ngb Gene and Its Regulation 
6.1. Neuron-Specific Expression of Ngb Gene 
From the beginning of its discovery, Ngb gene expression has been found to be highly 
tissue-specific. In situ hybridization showed that Ngb mRNA was widely distributed throughout the 
adult rat brain, including cerebral cortex, hippocampus, and subcortical structures such as thalamus, 
hypothalamus, olfactory bulb, and cerebellum [33,80,81]. The distribution of Ngb protein is consistent 
with its mRNA localization, and the subcellular immunoreactivity is restricted to the cytoplasm. Int. J. Mol. Sci. 2012, 13 7003 
 
Among all Ngb-expressing cells, the highest expression is seen in the retina, with the
 estimated 
concentration about
 100-fold higher than in the brain [82]. Ngb mRNA was detected in the perikarya of 
the nuclear
 and ganglion layers of the neuronal retina, whereas the protein
 was present mainly in the 
plexiform layers and in the ellipsoid
 region of the photoreceptor inner segment [83]. The distribution 
of Ngb correlates with the subcellular localization of mitochondria and
 with the relative oxygen 
demands. These findings
 suggest that Ngb supplies oxygen to the retina, similar
 to myoglobin in the 
myocardium and skeletal muscle. Although Ngb concentration in the brain is relatively lower than in 
the retina, considering that the neuron is the major cell type in the brain specifically expressing Ngb, 
thus Ngb may be a unique molecule that plays certain roles in maintaining normal neuron function and 
protectively responding to pathological insults.   
6.2. Ngb Gene Expression under Pathological Conditions   
The expression of Ngb gene is up-regulated under hypoxic/ischemic conditions both in cultured 
cells [84,85] and in stroke animal brains [2,6,86,87]. Ngb is also up-regulated in the cerebellum of 
mouse pups in response to hypoxic-ischemic insults caused by maternal seizures during intrauterine 
life [29]. These data imply that Ngb up-regulation could be an endogenous compensatory or protective 
mechanism in response to the sublethal hypoxic/ischemic insults to brain neurons. More importantly, a 
recent report showed that Ngb expression is increased in the cortical peri-infarct region in stroke 
patients, suggesting its clinical relevance for endogenous neuroprotection [88]. In contrast to acute 
hypoxic conditions, a chronic hypoxia (10% oxygen for 14 days) did not increase Ngb gene expression 
in mRNA or protein level in the mouse [89]. Moreover, two-hour exposure of mice to 7.6% oxygen 
did not up-regulate brain Ngb either [83]. However, others reported opposite results that housing rats 
in 10% oxygen for up to 14 days up-regulated Ngb mRNA in the rat brain [90]. Thus, there might also 
be species- and condition-dependent differences for Ngb responses to hypoxic conditions. In addition 
to hypoxia/ischemia, aging might also be an influential factor for Ngb expression. Sun et al. have 
demonstrated that Ngb expression level decreased to about a half in aged rats (24 months) compared to 
young ones (3, 12 months) in various regions of brain, implying the pathophysiological importance of 
Ngb in age-related neurodegenerative diseases [44].   
6.3. Transcriptional Regulation of Ngb Gene 
A few recent studies focused on the transcriptional regulation mechanisms of Ngb gene expression. 
Zhang et al. reported that transcription factors Sp1 and Sp3 can bind to the human Ngb promoter 
region and are responsible for transactivation of Ngb promoter [91]. Our lab has analyzed the core 
promoter region of the mouse Ngb gene, and further characterized the transcription factors required for 
Ngb gene expression under both resting and hypoxic conditions [92]. We located the core promoter of 
mouse Ngb gene to the 554 bp segment before the transcription start codon. Complementary approaches 
have demonstrated that transcription factors, NFκB family members (p65, p50, cRel), Egr1, and Sp1 
bind the Ngb promoter, and are responsible for basal Ngb expression. Moreover, NFκB (p65) and Sp1, 
as well as Hif1α, were also responsible for hypoxia-induced up-regulation of Ngb expression. These 
findings will be helpful in establishing strategies to screen for compounds that can up-regulate 
endogenous Ngb gene expression. Int. J. Mol. Sci. 2012, 13 7004 
 
6.4. Ngb Gene Expression in Non-Neuronal Cells 
Besides brain neurons and the retina, Ngb expression could also be detected in other tissues such as 
pancreas, adrenal gland and testes, but the expression level was lower [93]. It was reported that Ngb 
mRNA is detectable in cultured astrocytes from newborn mouse brain, and that Ngb protein co-localizes 
with glial fibrillary acid protein (GFAP) in cultured astrocytes [94]. Moreover, a number of studies 
have demonstrated that Ngb was expressed in various tumor tissues, including glioblastoma [95,96] and 
astrocytoma [97]. These findings imply a broader involvement of Ngb under pathological conditions in 
different tissues, and suggest Ngb may be related to the adaptation of tumor cells to hypoxic 
microenvironments, which is consistent with its role in oxygen sensing and hypoxic signaling.   
Overall, emerging data have clearly documented that up-regulation of Ngb gene expression is 
neuroprotective against hypoxic/ischemic brain injury [5,26], therefore targeting Ngb for endogenous 
neuroprotection would be translationally significant. We need to seek strategies to identify small 
molecules that elevate endogenous Ngb, which would help us in the development of new therapy 
approaches for stroke and other related neurological disorders.   
7. Targeting Ngb for Endogenous Neuroprotection 
7.1. Previously Identified Chemical Compounds that Up-Regulate Endogenous Ngb Expression 
As described earlier (Section 2), a few chemical compounds have been identified that are able to 
up-regulate endogenous Ngb gene expression, including valproic acid (VPA), cinnamic acid and 
17β-estradiol (E2) [16,17]. VPA and cinnamic acid were identified in a small-scale screening for Ngb 
up-regulators in cultured neuroblastoma cell line HN33 [16]. Interestingly, earlier studies have already 
shown that VPA was protective in rodent models of cerebral ischemia [20,22]. VPA is a commonly 
used drug to treat seizures and bipolar mood disorder, which at least in part warrants its clinical safety. 
However, previous studies suggested that the neuroprotective effect of VPA was through its function in 
histone deacetylase (HDAC) inhibition, and it is unclear whether Ngb induction plays a role in VPA 
neuroprotection. Cinnamic acid is a natural substance obtained from cinnamon oil. Cinnamic acid 
reduced glutamate toxicity in primary cultured rat cortical neurons [27], but did not protect GT1-7 
(immortalized mouse hypothalamic) cells from oxygen and glucose deprivation (OGD) [28] in vitro. 
Another study also showed negative result of cinnamic acid in protection against beta-amyloid-induced 
toxicity in a rat-derived neuronal cell line [98]. These studies cast doubt on the neuroprotective effect 
of cinnamic acid in animal stroke models, which nevertheless is worth investigating in the future. 
17β-estradiol (E2) was found to upregulate Ngb expression in both the SK-N-BE human 
neuroblastoma cell line and mouse hippocampal neurons [17]. As a type of estrogen, E2 has been 
reported to be protective for neuronal cells against a variety of insults, including H2O2 [99,100] and 
oxygen-glucose deprivation [101]. E2 can also attenuate the toxicity of beta-amyloid and glutamate in 
a hippocampal cell line [102]. In addition, estrogen therapy in post-menopausal women is associated 
with decreased incidence and enhanced recovery from ischemic stroke [103]. However, a serious 
drawback of E2 is its potential in carcinogenesis. E2 exposure to postmenopausal women is associated 
with an increased risk of endometrial and breast cancer [104,105]. Animal studies further confirmed Int. J. Mol. Sci. 2012, 13 7005 
 
the tumorigenesis caused by E2 administration [106,107]. Thus the prospect of E2 as a neuroprotective 
reagent looks slim.   
It should be noted that the Ngb-upregulation effect of the above three molecules were all discovered 
in neuron cultures, thus many issues remain to be investigated, e.g., their Ngb regulation effect in 
animal models, the function and specificity of Ngb regulation. These three molecules need to be 
further studied as to whether they can be developed into therapeutic molecules via up-regulating Ngb. 
We expect that more small molecules may be Ngb upregulators and additional screening is necessary. 
As the availability of positive controls in screening assay is critical, it is necessary to justify in 
different models whether VPA, cinnamic acid and E2 can serve as positive controls for future 
screening to identify more Ngb upregulators.   
7.2. Establishment of a Cell-based High Throughput Screening System for Identification of Small 
Molecules Capable of Ngb Upregulation 
Our laboratory has just started to establish a cell-based high throughput screening (HTS) system for 
identifying novel small molecules capable of up-regulating Ngb expression. This screening approach 
has been successfully used in searching compounds for up-regulating intracellular proteins [108]. For 
example, activation of NF-κB has been targeted in a cell-based high-throughput screening to identify 
neuroprotectants [9]. A number of identified small molecules are being tested in preclinical animal 
studies, some of them initially showed promising results [109–111].   
Generally, HTS incorporates two steps: (1) Establishment of a biological detection system;  
(2) Screening and validation of effective compounds. A common method of biological detection for 
transcriptional activation is to employ a cell-based assay with a reporter gene driven by the key 
promoter elements of the target gene. A popularly applied reporter gene is the firefly luciferase gene, 
due to its high sensitivity and cost efficiency [108,112]. In practice, the very first task before 
establishing the detection system is to identify the promoter of the target gene and then develop a 
reporter construct with this promoter. For Ngb, one study has identified a 2.0 kb promoter region for 
human Ngb gene [113]. Our recently published study further located the core promoter region of 
mouse Ngb gene to the 554 bp fragment before the transcription start codon [92]. This promoter region 
will be used to make luciferase reporter constructs. 
A standard drug development procedure goes from cell assay to animal model, and eventually to 
clinical trial. An ideal compound would be able to induce the expression of endogenous 
neuroprotective molecules in both animal and human neurons and brains, therefore it is necessary to 
establish both mouse and human cell-based reporter constructs, i.e., Ngb promoter-driven luciferase 
construct, for Ngb up-regulation compound screening, and to subsequently generate stable cell lines 
containing this Ngb reporter construct [110].   
Once the stable cell lines containing Ngb reporter construct has been validated, compound 
screening can be performed on a cell-based high throughput assay system [114]. The identified 
compounds that can up-regulate Ngb expression should then be validated as follows: (1) Only the 
compounds that can up-regulate both mouse and human Ngb promoter activities will undergo further 
investigations; (2) To determine whether changes of Ngb reporter activities truly reflect endogenous 
Ngb mRNA or protein alterations, effects of selected compounds in Ngb mRNA or protein levels of Int. J. Mol. Sci. 2012, 13 7006 
 
cultured cell lines and primary neurons need to be examined by quantitative RT-PCR and Western blot 
for validation; (3) We need to validate the neuroprotective effects of these compounds against neuronal 
injury induced by OGD or other insults in neuron cultures; (4) Lastly, we need to validate the ability of 
the selected compounds in up-regulating Ngb in mouse brain and their neuroprotection against cerebral 
ischemia in mouse models.   
We acknowledge that several technological issues require attention in the HTS process. For example, 
a certain amount of small molecules are interesting during the screening, however, some of them may 
turn out to be false positives during further validation and optimization, typically after a great deal of 
time and resources have been devoted, thus it would be critical to minimize false positives during the 
early screening stages [115]. The HTS process consists of multiple automated steps involving compound 
handling, liquid transfers, and assay signal capture, all of which unavoidably contribute to systematic 
variation in the screening data. It will be challenging to distinguish biologically active compounds from 
assay variability [116]. We may also need to consider building knowledge equity from the integration of 
multiple parallel screening assays, workstreams and data sources [117]. Lastly, statistical analysis of the 
screening data may also result in false positives or false negatives, therefore it is essential to apply robust 
statistical methods effectively and properly for decision-making [115,116,118]. 
In summary, the strategy we described above comprises two translational features. First, we will 
establish both mouse and human stable cell lines with Ngb promoter reporter to ensure that selected 
compounds are capable of activating both mouse and human Ngb promoters. Second, validation as the key 
component will be conducted in every step of small molecule screening and therapeutic development. The 
general strategy of this small molecule screening system is summarized in Figure 2.   
Figure 2. Strategy of small molecule screening for chemical compounds capable of 
up-regulating Ngb gene expression. The key steps in this strategy include: (1) Characterization 
of Ngb promoter using bioinformatics tools and luciferase reporter construct; (2) Establishment 
of stable cell lines that express reporter genes driven by Ngb promoter; (3) Screening and 
validation of chemical compounds that can up-regulate Ngb expression and be neuroprotective. 
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